Cargando…

The challenges of clinical trials in fragile X syndrome

RATIONALE: Advances in understanding the underlying mechanisms of conditions such as fragile X syndrome (FXS) and autism spectrum disorders have revealed heterogeneous populations. Recent trials of novel FXS therapies have highlighted several challenges including subpopulations with possibly differe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacquemont, Sébastien, Berry-Kravis, Elizabeth, Hagerman, Randi, von Raison, Florian, Gasparini, Fabrizio, Apostol, George, Ufer, Mike, Des Portes, Vincent, Gomez-Mancilla, Baltazar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932172/ https://www.ncbi.nlm.nih.gov/pubmed/24173622 http://dx.doi.org/10.1007/s00213-013-3289-0

Ejemplares similares

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents
por: Hagerman, Randi, et al.
Publicado: (2018)

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome
por: Jacquemont, Sébastien, et al.
Publicado: (2018)

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome
por: Jacquemont, Sébastien, et al.
Publicado: (2018)

Fragile X Premutation
por: Tassone, Flora, et al.
Publicado: (2014)

Aging in fragile X syndrome
por: Utari, Agustini, et al.
Publicado: (2010)

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome
por: Brasa, Sarah, et al.
Publicado: (2016)

Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome
por: Hessl, David, et al.
Publicado: (2019)

Fragile X syndrome and fragile X-associated disorders
por: Rajaratnam, Akash, et al.
Publicado: (2017)

Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study
por: Bailey, Donald B., et al.
Publicado: (2015)

Fragile X Syndrome
por: McLennan, Yingratana, et al.
Publicado: (2011)

Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
por: Luu, Skylar, et al.
Publicado: (2020)

Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017)

Best Practices in Fragile X Syndrome Treatment Development
por: Erickson, Craig A., et al.
Publicado: (2018)

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments
por: Hagerman, Randi, et al.
Publicado: (2010)

Fragile X Premutation: Medications, Therapy and Lifestyle Advice
por: Sodhi, Deepika Kour, et al.
Publicado: (2021)

Targeted treatments for fragile X syndrome
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2011)

Fragile X-Associated Neuropsychiatric Disorders (FXAND) in Young Fragile X Premutation Carriers
por: Aishworiya, Ramkumar, et al.
Publicado: (2022)

Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems
por: Hagerman, Randi J, et al.
Publicado: (2008)

Fragile X Syndrome
por: Saldarriaga, Wilmar, et al.
Publicado: (2014)

Intercorrelation of Molecular Biomarkers and Clinical Phenotype Measures in Fragile X Syndrome
por: Aishworiya, Ramkumar, et al.
Publicado: (2023)

Cardiovascular Problems in the Fragile X Premutation
por: Tassanakijpanich, Nattaporn, et al.
Publicado: (2020)

Modulation of the GABAergic pathway for the treatment of fragile X syndrome
por: Lozano, Reymundo, et al.
Publicado: (2014)

Fragile X targeted pharmacotherapy: lessons learned and future directions
por: Erickson, Craig A., et al.
Publicado: (2017)

Fragile X Syndrome in children
por: Acero-Garcés, David O., et al.
Publicado: (2023)

Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers
por: Polussa, Jonathan, et al.
Publicado: (2014)

Case Reports of Aortic Aneurism in Fragile X Syndrome
por: Lewis, Sivan, et al.
Publicado: (2022)

Descriptive analysis of seizures and comorbidities associated with fragile X syndrome
por: Albizua, Igor, et al.
Publicado: (2022)

Fragile X-Associated Tremor/Ataxia Syndrome: Unmet Needs and a Path for the Future
por: Hall, Deborah A., et al.
Publicado: (2018)

Genomic studies in fragile X premutation carriers
por: Lozano, Reymundo, et al.
Publicado: (2014)

New Targeted Treatments for Fragile X Syndrome
por: Protic, Dragana, et al.
Publicado: (2019)

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
por: Berry-Kravis, E, et al.
Publicado: (2009)

Fragile X-Associated Neuropsychiatric Disorders (FXAND)
por: Hagerman, Randi J., et al.
Publicado: (2018)

Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2012)

Neural progenitor cells from an adult patient with fragile X syndrome
por: Schwartz, Philip H, et al.
Publicado: (2005)

FMR1 premutation with Prader–Willi phenotype and fragile X‐associated tremor/ataxia syndrome
por: Martínez‐Cerdeño, Verónica, et al.
Publicado: (2017)

Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization
por: Cordeiro, Lisa, et al.
Publicado: (2010)

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2022)

Intranuclear inclusions in a fragile X mosaic male
por: Pretto, Dalyir I, et al.
Publicado: (2013)

Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature
por: Tartaglia, Nicole, et al.
Publicado: (2019)

EEG Signal Complexity Is Reduced During Resting-State in Fragile X Syndrome
por: Proteau-Lemieux, Mélodie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q9lhe2eedc4875uiel7onoj0q7